Selective Anticancer Effects of Portulaca grandiflora via Apoptosis and NF-κB Pathway Modulation in MDA-MB-231 Cells

Hina Salahuddin1, Riffat Batool2, Ejaz Aziz3

  • 1Department of Zoology, University of Okara, Okara, Pakistan.

Insights

Portulaca grandiflora extracts show potential against aggressive triple-negative breast cancer (TNBC). Methanolic extract (PGM) selectively induces apoptosis and inhibits metastasis by suppressing NF-κB signaling in TNBC cells.

Area of Science:

  • Phytochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is aggressive and resistant to conventional treatments.
  • Plant-derived compounds offer potential therapeutic alternatives with selective cytotoxicity.
  • Portulaca grandiflora is rich in phytochemicals with known anticancer properties.

Purpose of the Study:

  • To evaluate the pro-apoptotic and anti-metastatic potential of Portulaca grandiflora extracts against TNBC.
  • To investigate the underlying mechanisms, including NF-κB signaling pathway modulation.
  • To assess the selective toxicity of the extracts towards TNBC cells.

Main Methods:

  • Cytotoxicity screening using MTT assay on MDA-MB-231 TNBC and MCF-10A cells.
  • Apoptosis induction analysis via cell cycle, Annexin V/PI staining, DNA fragmentation, and caspase assays.
  • NF-κB signaling pathway evaluation using Western blot, luciferase reporter, and DNA-binding assays.
  • Migration and invasion assays (wound healing, transwell) to assess anti-metastatic effects.

Main Results:

  • Methanolic extract (PGM) exhibited potent antiproliferative activity (IC₅₀ = 79.5 µg/mL) with minimal toxicity to normal breast cells.
  • Both PGM and n-hexane extract (PGH) induced apoptosis and cell cycle arrest in TNBC cells.
  • PGM significantly inhibited NF-κB DNA-binding activity, reduced key signaling proteins (IκBα, TAK1, Akt), and decreased survival factors (Bcl-2, survivin).
  • Significant suppression of migration and invasion in TNBC cells was observed with PGM treatment.

Conclusions:

  • Portulaca grandiflora extracts, particularly PGM, demonstrate selective induction of apoptosis and anti-metastatic effects in TNBC.
  • Suppression of the NF-κB signaling pathway is a key mechanism underlying the observed anticancer activity.
  • These findings support the potential of P. grandiflora as a source for novel TNBC therapeutics.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...